"1. Introduction
... Between 11–18 December 2020, the US Food and Drug Administration (FDA) issued Emergency Use Authorisations (EUA) for two vaccines based on messenger RNA (mRNA) technology to protect against the COVID-19 disease: the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) and the mRNA-1273 COVID-19 vaccine (Moderna), with the recommendation for a two-dose regimen. Shortly afterward, intense vaccination campaigns began in many countries worldwide, leading to the current status of a fully vaccinated population exceeding 4 billion people. Initially, the vaccination program generated concerns regarding this novel technology based on genetic material, and encountered resistance in many countries worldwide. One of the main concerns in the general population was the risk of potentially unknown side effects of the vaccine, especially long-term side effects, related to the rapid development and registration process...
One of the major concerns regarding these vaccines was related to the link between mRNA vaccines and malignancy, especially hematologic malignancies... In this paper, we present two cases of hematologic malignancies: diffuse large B-cell lymphoma and T/NK-cell lymphoma, diagnosed shortly after the administration of the mRNA COVID-19 (Pfizer-BioNTech) vaccine...
3. Discussions
... The emergence of hematologic malignancies, such as the non-Hodgkin lymphomas presented in our paper, although only temporarily [sic] linked with mRNA COVID-19 vaccination, requires an in-depth investigation into potential underlying interrelations. Until now, isolated cases of newly diagnosed or recurrent hematologic malignancies shortly after COVID-19 vaccination have been reported. Brumfiel et al. presented a case of recurrent cutaneous anaplastic large-cell lymphoma (CD30 positive). The patient developed an ulcerated axillary lesion two days after the first dose of the BNT162b2 vaccine in the ipsilateral arm, raising suspicion of a possible link between these two events. Goldman et al. reported a clinical case of rapid progression in angioimmunoblastic T-cell lymphoma, objectified through serial PET/CT scans performed after the BNT162b2 mRNA vaccine booster dose administration. Several days after the third dose inoculation, the patient noticed a significant enlargement of the cervical lymph nodes. The PET/CT scan revealed increased activity in the pre-existing areas, as well as new hypermetabolic nodal and extranodal sites. Similar isolated cases of lymphoproliferative disorders have been reported after viral vector COVID-19 vaccines as well."
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).